Zomedica Corp. (AMEX:ZOM) finished Thursday with an addition of $0.01 to close at $0.21, an upside of 1.12 percent. An average of 4,678,840 shares of common stock have been traded in the last five days. There was a gain of $0.0012 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 4,139,955 shares traded, while the 50-day average volume stands at 4,241,576.
ZOM stock has decreased by -10.54% in the last month. The company shares reached their 1-month lowest point of $0.1990 on 07/20/23. With the stock rallying to its 52-week high on 01/18/23, shares of the company touched a low of $0.15 and a high of $0.39 in 52 weeks. It has reached a new high 6 times so far this year and achieved 27.12% or $0.0442 in price. In spite of this, the price is down -46.87% from the 52-week high.
Valuation Metrics
Zomedica Corp. (ZOM) stock’s beta is 0.96. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 9.58, the price-to-book (PB) ratio at 0.77.
Financial Health
The quick ratio of Zomedica Corp. for the three months ended March 30 was 14.80, and the current ratio was 15.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.01 for the quarter ending March 30. Zomedica Corp.’s EBITDA margin for the year ending March 30 is -94.46%. Its gross profit as reported stood at $13.65 million compared to revenue of $18.93 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Zomedica Corp.’s return on assets was -7.00%.
Earnings Surprise
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$6.39 million in the quarter, while revenues of -$2.81 million were grew 38.34%. The analyst consensus anticipated Zomedica Corp.’s latest quarter earnings to come in at $0 per share, but it turned out to be -$0.01. For the quarter, EBITDA amounted to -$6.8 million. Shareholders own equity worth $979.95 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Zomedica Corp. (ZOM) price momentum. RSI 9-day as of the close on 10 August was 47.32%, suggesting the stock is Neutral, with historical volatility in this time frame at 44.07%.
As of today, ZOM’s price is $0.2098 +0.58% or $0.0012 from its 5-day moving average. ZOM is currently trading -7.29% lower than its 20-day SMA and +9.05% higher than its 100-day SMA. However, the stock’s current price level is +6.04% above the SMA50 and -5.82% below the SMA200.
The stochastic %K and %D were 34.45% and 44.60%, respectively, and the average true range (ATR) was 0.0105. With the 14-day stochastic at 36.00% and the average true range at 0.0105, the RSI (14) stands at 48.70%. The stock has reached -0.0034 on the 9-day MACD Oscillator while the 14-day reading was at -0.0021.
Analyst Ratings
Dawson James launched coverage on Zomedica Corp. (AMEX: ZOM) in its analyst report released on January 06, 2023. The firm assigned the stock a Buy rating. The consensus rating for Zomedica Corp. (ZOM) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ZOM, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is ZOM’s price target for the next 12 months?
Analysts predict a range of price targets between $0.44 and $0.44, with a median target of $0.44. Taking a look at these predictions, the average price target given by analysts for Zomedica Corp. (ZOM) stock is $0.44.
